Comment on: Immunotherapy-based firstline treatment of intermediate- and poorrisk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

Leonart, Letícia Paula; Riveros, Bruno Salgado; Berlinski, Felipe; Rego, Maria Aparecida do Carmo

Comment on: Immunotherapy-based firstline treatment of intermediate- and poorrisk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system / Comentário sobre: Tratamento baseado em imunoterapia para primeira linha do carcinoma renal avançado com risco intermediário ou alto: número necessário para tratar e custo para prevenir um evento na perspectiva do sistema privado de saúde brasileiro

Leonart, Letícia Paula; Riveros, Bruno Salgado; Berlinski, Felipe; Rego, Maria Aparecida do Carmo.

Leonart, Letícia Paula; MSD Brasil. São Paulo, SP. BR
Riveros, Bruno Salgado; MSD Brasil. São Paulo, SP. BR
Berlinski, Felipe; MSD Brasil. São Paulo, SP. BR
Rego, Maria Aparecida do Carmo; MSD Brasil. São Paulo, SP. BR

J. bras. econ. saúde (Impr.) ; 14(3): 267-268, dezembro 2022.

Article in English | LILACS, ECOS | ID: biblio-1414913

Subject(s)

Carcinoma, Renal Cell; Immunotherapy

Fulltext

XML

Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Carcinoma, Renal Cell / Immunotherapy Type of study: Health economic evaluation / Risk factors Country/Region as subject: South America / Brazil Language: English Journal: J. bras. econ. saúde (Impr.) Journal subject: Medicine Year: 2022 Type: Article Affiliation country: Brazil Institution/Affiliation country: MSD Brasil/BR

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google